8. Huntington disease
197 clinical trials, 171 drugs (DrugBank: 54 drugs), 82 drug target genes, 144 drug target pathways
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04478734 (ClinicalTrials.gov) | January 1, 2021 | 11/2/2020 | Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease | Multicentric Trial on the Use of Combined Therapy of Thiamine and Biotine in Patients With Huntington´s Disease | Huntington Disease | Drug: Moderate doses of Thiamine y Biotin;Drug: High doses of Thiamine y Biotin | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Ciberned (Centro de Investigación Biomédica en Red) | Not yet recruiting | 18 Years | N/A | All | 24 | Phase 2 | Spain |
| 2 | EUCTR2020-002822-10-DE (EUCTR) | 11/12/2020 | 06/11/2020 | A study of Pridopidine in Patients with Early Stage of Huntington Disease | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease - PRidopidine Outcome on Function in Huntington Disease (PROOF-HD) | Huntington Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: PL101 INN or Proposed INN: PRIDOPIDINE HYDROCHLORIDE Other descriptive name: Pridiopidine | Prilenia Neurotherapeutics Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 480 | Phase 3 | United States;European Union;Canada;Germany;United Kingdom | ||
| 3 | NCT04556656 (ClinicalTrials.gov) | October 16, 2020 | 14/9/2020 | PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease | Huntington Disease | Drug: Pridopidine;Drug: Placebo | Prilenia | NULL | Recruiting | 25 Years | N/A | All | 480 | Phase 3 | United States |
| 4 | NCT04421339 (ClinicalTrials.gov) | October 7, 2020 | 4/6/2020 | Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study | Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study | Huntington Disease | Dietary Supplement: Melatonin;Other: Placebo | The University of Texas Health Science Center, Houston | Huntington's Disease Society of America | Recruiting | 18 Years | 75 Years | All | 20 | N/A | United States |
| 5 | EUCTR2018-003898-94-NL (EUCTR) | 01/10/2020 | 08/10/2020 | An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients with Huntington’s Disease | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 INN or Proposed INN: tominersen Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx | F.Hoffmann La-Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1050 | Phase 3 | United States;Spain;Austria;Chile;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;New Zealand | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04400331 (ClinicalTrials.gov) | September 18, 2020 | 19/5/2020 | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease | Chorea, Huntington | Drug: Valbenazine | Neurocrine Biosciences | Huntington Study Group | Enrolling by invitation | 18 Years | 75 Years | All | 120 | Phase 3 | United States |
| 7 | NCT04301726 (ClinicalTrials.gov) | September 1, 2020 | 13/2/2020 | Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD | Efficacy of Deutetrabenazine in Huntington's Disease Patients With Dysphagia: A Randomised, Placebo-controlled Pilot Study | Huntington Disease | Drug: Deutetrabenazine Oral Tablet [Austedo];Drug: Placebo oral tablet | Fundacion Huntington Puerto Rico | NULL | Not yet recruiting | 21 Years | N/A | All | 48 | Phase 1 | NULL |
| 8 | NCT04514367 (ClinicalTrials.gov) | August 17, 2020 | 27/7/2020 | An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease | A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease | Huntington Disease | Drug: ANX005 | Annexon, Inc. | NULL | Recruiting | 18 Years | N/A | All | 24 | Phase 2 | United States |
| 9 | NCT04201834 (ClinicalTrials.gov) | August 13, 2020 | 13/12/2019 | Risperidone for the Treatment of Huntington's Disease Involuntary Movements | Risperidone for the Treatment of Huntington's Disease Chorea | Huntington Disease;Chorea | Drug: Risperidone;Device: BioStamp nPoint device | University of Rochester | NULL | Recruiting | 18 Years | 65 Years | All | 12 | Phase 2 | United States |
| 10 | EUCTR2019-003637-42-DE (EUCTR) | 28/07/2020 | 09/06/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2019-002178-30-DE (EUCTR) | 28/07/2020 | 12/06/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease | Huntington’s Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120102 Product Code: WVE-120102 INN or Proposed INN: WVE-120102 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 12 | EUCTR2019-003637-42-DK (EUCTR) | 06/07/2020 | 02/03/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.1;Level: LLT;Classification code 10012278;Term: Dementia due to Huntington's disease;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | France;Canada;Poland;Australia;Denmark;Germany;United Kingdom | ||
| 13 | NCT04617847 (ClinicalTrials.gov) | April 13, 2020 | 30/10/2020 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's Disease | Huntington Disease | Drug: WVE-120101 | Wave Life Sciences Ltd. | NULL | Enrolling by invitation | N/A | N/A | All | 60 | Phase 1;Phase 2 | Australia;Canada;Denmark;France;Germany;Poland;United Kingdom |
| 14 | EUCTR2019-003637-42-PL (EUCTR) | 11/04/2020 | 19/02/2020 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 15 | EUCTR2019-002178-30-DK (EUCTR) | 22/01/2020 | 18/09/2019 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease | Huntington’s Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120102 Product Code: WVE-120102 INN or Proposed INN: WVE-120102 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | France;Canada;Poland;Australia;Denmark;Germany;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT04219241 (ClinicalTrials.gov) | January 2020 | 11/12/2019 | Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. | Clinical Extension Study for Assessing the Safety and Efficacy of the Intravenous Administration of Cellavita-HD in Huntington's Disease Patients Who Participated in the ADORE-DH Study. | Huntington Disease | Biological: Cellavita-HD | Azidus Brasil | Cellavita Pesquisa Científica Ltda | Not yet recruiting | 21 Years | 65 Years | All | 35 | Phase 2;Phase 3 | Brazil |
| 17 | NCT04102579 (ClinicalTrials.gov) | November 13, 2019 | 23/9/2019 | Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease | Chorea, Huntington | Drug: Valbenazine;Drug: Placebo | Neurocrine Biosciences | Huntington Study Group | Recruiting | 18 Years | 75 Years | All | 120 | Phase 3 | United States;Canada |
| 18 | EUCTR2019-002178-30-PL (EUCTR) | 29/10/2019 | 13/08/2019 | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease | Huntington’s Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120102 Product Code: WVE-120102 INN or Proposed INN: WVE-120102 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 19 | NCT04071639 (ClinicalTrials.gov) | October 20, 2019 | 26/8/2019 | Symptomatic Therapy for Patients With Huntington's Disease | Randomized Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients | Huntington Disease | Drug: Haloperidol;Drug: Risperidone;Drug: Zoloft;Drug: Coenzyme Q10 | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Recruiting | N/A | N/A | All | 100 | Phase 1 | China |
| 20 | NCT04617860 (ClinicalTrials.gov) | September 24, 2019 | 30/10/2020 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients With Huntington's Disease | Huntington Disease | Drug: WVE-120102 | Wave Life Sciences Ltd. | NULL | Enrolling by invitation | N/A | N/A | All | 60 | Phase 1;Phase 2 | Australia;Canada;Denmark;France;Germany;Poland;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT04000594 (ClinicalTrials.gov) | September 2, 2019 | 26/6/2019 | A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease | An Open-Label, Adaptive Multiple-Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease | Huntingtons Disease | Drug: RO7234292 (RG6042) | Hoffmann-La Roche | NULL | Recruiting | 25 Years | 65 Years | All | 20 | Phase 1 | Netherlands;United Kingdom |
| 22 | NCT03854019 (ClinicalTrials.gov) | August 5, 2019 | 22/2/2019 | Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease | Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease | Huntington Disease;Irritability | Drug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);Drug: Placebo | The University of Texas Health Science Center, Houston | Cures Within Reach | Recruiting | 18 Years | 75 Years | All | 22 | Phase 3 | United States |
| 23 | EUCTR2018-002987-14-NL (EUCTR) | 23/07/2019 | 25/02/2019 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's disease | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | F.Hoffmann La-Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;New Zealand | |||
| 24 | EUCTR2016-005095-10-FR (EUCTR) | 11/07/2019 | 05/03/2019 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Wave Life Science Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | |||
| 25 | EUCTR2016-005142-39-FR (EUCTR) | 09/07/2019 | 21/05/2019 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | Huntington’s Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | WAVE Life Sciences Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT03980938 (ClinicalTrials.gov) | July 8, 2019 | 7/6/2019 | Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease | A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) | Huntington Disease | Drug: neflamapimod;Other: Placebo | EIP Pharma Inc | Voisin Consulting, Inc. | Recruiting | 30 Years | 70 Years | All | 16 | Phase 2 | United Kingdom |
| 27 | EUCTR2018-004840-51-GB (EUCTR) | 26/06/2019 | 22/03/2019 | Study of Neflamapimod in Early-Stage Huntington Disease (HD) | A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) | Early-Stage Huntington Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | EIP Pharma, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 2 | United Kingdom | |||
| 28 | EUCTR2018-003898-94-ES (EUCTR) | 21/06/2019 | 11/06/2019 | An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients with Huntington’s Disease | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 900 | Phase 3 | United States;Spain;Austria;Russian Federation;Chile;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;New Zealand | |||
| 29 | NCT03842969 (ClinicalTrials.gov) | April 23, 2019 | 11/2/2019 | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies | An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease | Huntington Disease | Drug: RO7234292 (RG6042) | Hoffmann-La Roche | NULL | Recruiting | 25 Years | N/A | All | 1100 | Phase 3 | United States;Argentina;Australia;Austria;Canada;Germany;Italy;Netherlands;Spain;United Kingdom |
| 30 | EUCTR2018-002987-14-DK (EUCTR) | 11/04/2019 | 15/02/2019 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's disease | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | F.Hoffmann La-Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 800 | Phase 3 | United States;Spain;Austria;Russian Federation;Chile;Italy;Switzerland;United Kingdom;France;Canada;Argentina;Poland;Denmark;Australia;Netherlands;Germany;New Zealand;Japan;China | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2018-002987-14-AT (EUCTR) | 27/03/2019 | 22/03/2019 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's disease | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | F.Hoffmann La-Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand | |||
| 32 | EUCTR2018-002987-14-PL (EUCTR) | 19/03/2019 | 07/04/2020 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's disease | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 INN or Proposed INN: not available Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx | F.Hoffmann La-Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;Austria;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand | ||
| 33 | EUCTR2018-003898-94-GB (EUCTR) | 07/03/2019 | 13/12/2018 | An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients with Huntington’s Disease | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 INN or Proposed INN: tominersen Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx | F.Hoffmann La-Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1100 | Phase 3 | United States;Spain;Austria;Russian Federation;Chile;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand | ||
| 34 | NCT03787758 (ClinicalTrials.gov) | February 28, 2019 | 17/12/2018 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B | A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease | Huntington Disease | Drug: SAGE-718 | Sage Therapeutics | NULL | Completed | 18 Years | 70 Years | All | 6 | Phase 1 | United States |
| 35 | EUCTR2016-005095-10-DK (EUCTR) | 26/02/2019 | 20/12/2018 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 1;Phase 2 | France;Canada;Poland;Australia;Denmark;Germany;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2016-005142-39-DK (EUCTR) | 26/02/2019 | 20/12/2018 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | Huntington’s Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120102 Product Code: WVE-120102 INN or Proposed INN: WVE-120102 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 1;Phase 2 | United States;France;Canada;Poland;Australia;Denmark;Germany;United Kingdom | ||
| 37 | EUCTR2018-002987-14-GB (EUCTR) | 13/02/2019 | 08/02/2019 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's disease | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE | Huntington's disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | F.Hoffmann La-Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;Austria;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand | |||
| 38 | NCT03761849 (ClinicalTrials.gov) | January 23, 2019 | 30/11/2018 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease | Huntingtons Disease | Drug: RO7234292;Drug: Placebo | Hoffmann-La Roche | NULL | Active, not recruiting | 25 Years | 65 Years | All | 909 | Phase 3 | United States;Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;China |
| 39 | NCT03764215 (ClinicalTrials.gov) | November 15, 2018 | 27/11/2018 | Nilotinib in Huntington's Disease | An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease | Huntington Disease | Drug: Nilotinib 150 MG | Georgetown University | NULL | Recruiting | 25 Years | 90 Years | All | 10 | Phase 1 | United States |
| 40 | EUCTR2017-002471-25-GB (EUCTR) | 18/10/2018 | 04/08/2017 | An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVESTIGATIONAL STUDIES OF RO7234292 (ISIS 443139) | Early Manifest Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 INN or Proposed INN: n.a. Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx | F.Hoffmann La-Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 46 | Phase 1;Phase 2 | Canada;Germany;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT03575676 (ClinicalTrials.gov) | August 8, 2018 | 11/6/2018 | Efficacy and Safety of SOM3355 in Huntington's Disease Chorea | Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements. | Huntington's Chorea | Drug: SOM3355 100mg BID;Drug: SOM3355 200mg BID;Drug: Placebo BID | SOM Biotech SL | NULL | Completed | 18 Years | N/A | All | 32 | Phase 2 | Spain |
| 42 | EUCTR2016-005095-10-GB (EUCTR) | 02/08/2018 | 17/10/2017 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 1;Phase 2 | France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom | |||
| 43 | EUCTR2016-005142-39-GB (EUCTR) | 02/08/2018 | 19/05/2017 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | Huntington’s Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom | |||
| 44 | NCT02509793 (ClinicalTrials.gov) | August 1, 2018 | 24/7/2015 | A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) | A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) | Huntington's Disease | Drug: Tetrabenazine | William Ondo, MD | H. Lundbeck A/S | Recruiting | 18 Years | 80 Years | All | 20 | Phase 4 | United States |
| 45 | EUCTR2018-000203-16-ES (EUCTR) | 18/06/2018 | 21/05/2018 | Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. | Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. | Chorea movements associated with Huntington's Disease MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | SOM Biotech | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Spain | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT03713892 (ClinicalTrials.gov) | May 23, 2018 | 17/10/2018 | CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects | Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects | Huntington Disease | Drug: CKD-504;Drug: Placebo | Chong Kun Dang Pharmaceutical | NULL | Recruiting | 19 Years | 45 Years | All | 88 | Phase 1 | Korea, Republic of |
| 47 | NCT03252535 (ClinicalTrials.gov) | January 15, 2018 | 15/8/2017 | Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease | Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease | Huntington Disease | Biological: Cellavita HD lower dose;Biological: Cellavita HD higher dose;Other: Placebo | Azidus Brasil | Cellavita Pesquisa Científica Ltda | Active, not recruiting | 21 Years | 65 Years | All | 35 | Phase 2 | Brazil |
| 48 | EUCTR2017-002471-25-DE (EUCTR) | 10/01/2018 | 07/08/2017 | An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292 | An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | Early Manifest Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 INN or Proposed INN: n.a. Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx | F.Hoffmann La-Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 46 | Phase 2 | Canada;Germany;United Kingdom | ||
| 49 | NCT03342053 (ClinicalTrials.gov) | November 27, 2017 | 31/10/2017 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | Huntington's Disease | Drug: RO7234292 (RG6042) | Hoffmann-La Roche | NULL | Completed | 25 Years | N/A | All | 46 | Phase 2 | Canada;Germany;United Kingdom |
| 50 | NCT02728115 (ClinicalTrials.gov) | October 16, 2017 | 11/3/2016 | Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease | First in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease | Huntington Disease | Biological: Cellavita HD Lower Dose;Biological: Cellavita HD Higher dose | Azidus Brasil | Cellavita Pesquisa Científica Ltda;Azidus Brasil Scientific Research and Development Ltda | Active, not recruiting | 21 Years | 65 Years | Male | 6 | Phase 1 | Brazil |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT03296176 (ClinicalTrials.gov) | October 9, 2017 | 15/9/2017 | Metabolomic Study in Huntington's Disease (METABO-HD) | Metabolomic Study in Huntington's Disease | Huntington Disease | Biological: blood sample | University Hospital, Angers | NULL | Recruiting | 20 Years | 70 Years | All | 150 | N/A | France |
| 52 | NCT03225846 (ClinicalTrials.gov) | July 17, 2017 | 17/7/2017 | Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease | Huntington's Disease | Drug: WVE-120102;Drug: Placebo | Wave Life Sciences Ltd. | NULL | Recruiting | 25 Years | 65 Years | All | 60 | Phase 1;Phase 2 | Australia;Canada;Denmark;France;Germany;Poland;United Kingdom |
| 53 | NCT03225833 (ClinicalTrials.gov) | July 17, 2017 | 17/7/2017 | Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease | Huntington's Disease | Drug: WVE-120101;Drug: Placebo | Wave Life Sciences Ltd. | NULL | Recruiting | 25 Years | 65 Years | All | 60 | Phase 1;Phase 2 | Australia;Canada;Denmark;France;Germany;Poland;United Kingdom |
| 54 | NCT03515213 (ClinicalTrials.gov) | April 27, 2017 | 2/8/2017 | Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease | A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease | Huntington Disease | Drug: Fenofibrate;Drug: Placebo | University of California, Irvine | NULL | Active, not recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 55 | NCT03019289 (ClinicalTrials.gov) | April 19, 2017 | 3/1/2017 | A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | Health Volunteers, Huntington Disease | Drug: pridopidine (90 mg) | Prilenia | NULL | Completed | 25 Years | N/A | Male | 23 | Phase 1 | Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | EUCTR2016-003730-25-NL (EUCTR) | 14/02/2017 | 09/01/2017 | A study to assess the safety and efficacy of a new medicine SBT-020 in patients with Early Stage Huntington’s Disease. | A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease. - SBT-020 in HD | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SBT-020 Product Code: SBT-020 INN or Proposed INN: SBT-020 Other descriptive name: SS-20 | Stealth Bio Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | Netherlands | ||
| 57 | NCT02507284 (ClinicalTrials.gov) | May 10, 2016 | 22/7/2015 | Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease | An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD) | Irritable Mood;Huntington's Disease | Drug: SRX246;Drug: Placebo | Azevan Pharmaceuticals | National Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT Network | Completed | 18 Years | N/A | All | 106 | Phase 2 | United States |
| 58 | NCT02994719 (ClinicalTrials.gov) | March 1, 2016 | 21/12/2015 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | NULL | Active, not recruiting | 18 Years | 85 Years | All | 120 | United States | |
| 59 | NCT02907294 (ClinicalTrials.gov) | March 2016 | 8/3/2016 | Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers | Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers | Huntington Disease | Drug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: Placebo | Palobiofarma SL | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Terminated | 18 Years | 45 Years | Both | 8 | Phase 1 | Spain |
| 60 | EUCTR2015-000904-24-NL (EUCTR) | 15/02/2016 | 17/02/2016 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | EUCTR2014-005112-42-NL (EUCTR) | 11/12/2015 | 07/08/2015 | A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: Triheptanoin Product Code: UX007 | INSERM | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | France;Netherlands | ||
| 62 | EUCTR2015-000904-24-DE (EUCTR) | 03/12/2015 | 04/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Poland;Austria;Australia;France;United States;Canada;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 63 | EUCTR2015-000904-24-AT (EUCTR) | 18/11/2015 | 15/09/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Australia;Austria;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 64 | EUCTR2015-000904-24-GB (EUCTR) | 13/11/2015 | 18/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Austria;Australia;Russian Federation;Netherlands;Germany;Italy;United Kingdom | |||
| 65 | EUCTR2014-000418-75-NL (EUCTR) | 04/11/2015 | 15/10/2014 | A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug) | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) | Huntington's Disease (HD) MedDRA version: 18.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod capsules 0.5 mg Product Code: TV-5600 INN or Proposed INN: LAQUINIMOD Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Germany;Netherlands;Italy;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT02494778 (ClinicalTrials.gov) | September 24, 2015 | 7/7/2015 | A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD) | Huntington's Disease | Drug: Pridopidine | Prilenia | NULL | Terminated | 21 Years | N/A | All | 248 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;Denmark |
| 67 | EUCTR2015-000904-24-IT (EUCTR) | 15/09/2015 | 23/02/2018 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Italy | ||
| 68 | NCT02519036 (ClinicalTrials.gov) | August 6, 2015 | 1/8/2015 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease | Huntington's Disease | Drug: ISIS 443139 10 mg;Drug: ISIS 443139 30 mg;Drug: ISIS 443139 60 mg;Drug: ISIS 443139 90 mg;Drug: ISIS 443139 120 mg;Other: Placebo | Ionis Pharmaceuticals, Inc. | NULL | Completed | 25 Years | 65 Years | All | 46 | Phase 1;Phase 2 | Canada;Germany;United Kingdom |
| 69 | NCT02481674 (ClinicalTrials.gov) | July 2015 | 19/6/2015 | A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503) | A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 | Huntington's Disease | Drug: VX15/2503;Drug: Placebo | Vaccinex Inc. | Huntington Study Group | Completed | 21 Years | N/A | All | 301 | Phase 2 | United States;Canada |
| 70 | NCT02336633 (ClinicalTrials.gov) | July 2015 | 8/1/2015 | Resveratrol and Huntington Disease | Metabolic Intervention Using Resveratrol in Patients With Huntington Disease | Huntington Disease | Dietary Supplement: Resveratrol;Other: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | All | 102 | N/A | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT02453061 (ClinicalTrials.gov) | June 29, 2015 | 12/5/2015 | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | Huntington Disease | Drug: Triheptanoin oil;Drug: Placebo | Institut National de la Santé Et de la Recherche Médicale, France | Ultragenyx Pharmaceutical Inc | Active, not recruiting | 18 Years | N/A | All | 100 | Phase 2 | France;Netherlands |
| 72 | EUCTR2014-005112-42-FR (EUCTR) | 22/06/2015 | 22/06/2015 | A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | Huntington's disease MedDRA version: 18.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Product Name: Triheptanoin Product Code: UX007 | INSERM | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | France;Netherlands | ||
| 73 | EUCTR2014-004900-31-DE (EUCTR) | 27/05/2015 | 13/02/2015 | AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021 | AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021 | HUNTINGTON'S DISEASE MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 17.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: PF-02545920 INN or Proposed INN: not available Other descriptive name: PF-02545920 | Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 2 | United States;Canada;Poland;Germany;United Kingdom | ||
| 74 | EUCTR2014-001291-56-GB (EUCTR) | 24/04/2015 | 21/07/2014 | A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE | A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE | HUNTINGTON’S DISEASE MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 17.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 2 | United States;Canada;Poland;Germany;United Kingdom | |||
| 75 | EUCTR2013-001888-23-DK (EUCTR) | 13/04/2015 | 08/01/2015 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Denmark;Australia;Germany;Netherlands | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT02342548 (ClinicalTrials.gov) | February 25, 2015 | 15/1/2015 | Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 | An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021 | Huntington's Disease | Drug: 20 mg BID of PF-02545920 | Pfizer | NULL | Terminated | 30 Years | 66 Years | All | 188 | Phase 2 | United States;Canada;Germany;Poland;United Kingdom |
| 77 | EUCTR2014-000418-75-GB (EUCTR) | 30/01/2015 | 24/09/2014 | A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug) | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) | Huntington's Disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom | |||
| 78 | EUCTR2014-000418-75-DE (EUCTR) | 06/01/2015 | 25/09/2014 | A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug) | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) | Huntington's Disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod capsules 0.5 mg Product Code: TV-5600 INN or Proposed INN: LAQUINIMOD Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 79 | EUCTR2014-000418-75-CZ (EUCTR) | 05/01/2015 | 25/09/2014 | A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug) | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) | Huntington's Disease (HD) MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod capsules 0.5 mg Product Code: TV-5600 INN or Proposed INN: LAQUINIMOD Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 80 | EUCTR2014-000418-75-IT (EUCTR) | 18/11/2014 | 25/08/2014 | A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug) | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) | Huntington's Disease (HD) MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod capsules 0.5 mg Product Code: TV-5600 INN or Proposed INN: LAQUINIMOD Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Portugal;France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;United Kingdom;Italy | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | EUCTR2014-000418-75-PT (EUCTR) | 31/10/2014 | 25/09/2014 | A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug) | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) | Huntington's Disease (HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | United States;Portugal;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom | |||
| 82 | NCT02215616 (ClinicalTrials.gov) | October 28, 2014 | 12/8/2014 | A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod | A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease | Huntington's Disease | Drug: Laquinimod;Drug: Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Completed | 21 Years | 55 Years | All | 352 | Phase 2 | United States;Canada;Czechia;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;Czech Republic;France;India;Israel |
| 83 | EUCTR2014-001291-56-DE (EUCTR) | 27/10/2014 | 18/07/2014 | A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE | A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE | HUNTINGTON’S DISEASE MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 19.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: PF-02545920 INN or Proposed INN: not available Other descriptive name: PF-02545920 | Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 2 | United States;Canada;Poland;Germany;United Kingdom | ||
| 84 | EUCTR2014-000418-75-ES (EUCTR) | 23/10/2014 | 16/10/2014 | A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug) | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) | Huntington's Disease (HD) MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod capsules 0.5 mg Product Code: TV-5600 INN or Proposed INN: LAQUINIMOD Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | Portugal;France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;Italy;United Kingdom | ||
| 85 | NCT02231580 (ClinicalTrials.gov) | September 1, 2014 | 2/9/2014 | Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients | A Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's Disease | Huntington's Disease | Drug: BN82451B;Drug: Placebo | Ipsen | NULL | Terminated | 20 Years | 70 Years | Male | 17 | Phase 2 | Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | NCT02208934 (ClinicalTrials.gov) | September 2014 | 4/8/2014 | Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers | Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers | Huntington's Disease | Drug: PBF-999;Drug: Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Palo Biofarma, S.L | Completed | 18 Years | 45 Years | Male | 32 | Phase 1 | Spain |
| 87 | NCT02197130 (ClinicalTrials.gov) | September 2014 | 16/7/2014 | Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease | A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease | Huntington's Disease | Drug: PF-02545920;Other: Placebo | Pfizer | NULL | Completed | 30 Years | 65 Years | All | 272 | Phase 2 | United States;Canada;Germany;Poland;United Kingdom |
| 88 | NCT01834053 (ClinicalTrials.gov) | September 2014 | 11/4/2013 | Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. | Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial | Huntington Disease | Biological: autologous Stem Cell | Chaitanya Hospital, Pune | NULL | Recruiting | 35 Years | 44 Years | Both | 50 | Phase 1;Phase 2 | India |
| 89 | EUCTR2013-001888-23-PL (EUCTR) | 23/07/2014 | 14/05/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 90 | EUCTR2013-001888-23-AT (EUCTR) | 01/07/2014 | 08/01/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | EUCTR2013-002899-41-DE (EUCTR) | 28/04/2014 | 24/01/2014 | Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's disease | A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and thepharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male patients with Huntington’s disease | Huntington's disease MedDRA version: 18.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BN8251B INN or Proposed INN: N/A Other descriptive name: BN82451B Product Name: BN8251B INN or Proposed INN: N/A Other descriptive name: BN82451B | Ipsen Pharma | NULL | Not Recruiting | Female: no Male: yes | Phase 2 | Germany | |||
| 92 | EUCTR2013-001888-23-NL (EUCTR) | 07/04/2014 | 20/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany | ||
| 93 | EUCTR2013-001888-23-DE (EUCTR) | 25/03/2014 | 10/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 94 | EUCTR2013-001888-23-IT (EUCTR) | 13/03/2014 | 11/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany | ||
| 95 | NCT02006472 (ClinicalTrials.gov) | February 28, 2014 | 5/12/2013 | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease | Huntington's Disease | Drug: Pridopidine;Other: Placebo | Prilenia | European Huntington's Disease Network;Huntington Study Group | Completed | 21 Years | N/A | All | 408 | Phase 2 | United States;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | EUCTR2013-001888-23-GB (EUCTR) | 22/01/2014 | 27/11/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 97 | EUCTR2013-002545-10-SE (EUCTR) | 08/01/2014 | 11/11/2013 | An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. | An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309 | Parkinsons diseaseHuntingtons diseaseMultiple sclerosBrain traumaStrokeMyalgic encephalomyelitisNarcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: OSU6162 similar to (-)-OSU 6162 | A. Carlsson Research AB | NULL | Not Recruiting | Female: yes Male: yes | 240 | Phase 2 | Sweden | ||
| 98 | NCT02074410 (ClinicalTrials.gov) | January 2014 | 21/2/2014 | Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease | Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease | Huntington's Disease | Drug: OMS643762;Drug: Placebo | Omeros Corporation | NULL | Terminated | 18 Years | 65 Years | All | 22 | Phase 2 | United States |
| 99 | NCT01897896 (ClinicalTrials.gov) | November 12, 2013 | 14/6/2013 | Alternatives for Reducing Chorea in Huntington Disease | An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease | Chorea Associated With Huntington Disease | Drug: SD-809 | Auspex Pharmaceuticals, Inc. | NULL | Completed | 18 Years | N/A | All | 119 | Phase 3 | United States;Australia;Canada |
| 100 | NCT01806896 (ClinicalTrials.gov) | September 2013 | 6/3/2013 | Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease | A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease | Huntington's Disease | Drug: PF-02545920;Drug: Placebo | Pfizer | NULL | Completed | 18 Years | 70 Years | All | 37 | Phase 2 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT01795859 (ClinicalTrials.gov) | August 5, 2013 | 20/2/2013 | First Time Use of SD-809 in Huntington Disease | A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease | Chorea | Drug: SD-809;Drug: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 18 Years | N/A | All | 90 | Phase 3 | United States;Australia;Canada |
| 102 | NCT01882062 (ClinicalTrials.gov) | May 2013 | 18/6/2013 | Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease | Huntington Disease | Drug: Triheptanoin 1g/kg/day | Institut National de la Santé Et de la Recherche Médicale, France | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | France | |
| 103 | NCT01834911 (ClinicalTrials.gov) | March 2013 | 15/4/2013 | Effect of Tetrabenazine on Stroop Interference in HD | Effect of Tetrabenazine on Stroop Interference in Huntington Disease | Huntington Disease | Drug: Tetrabenazine withdrawal | New York Medical College | NULL | Completed | 18 Years | N/A | All | 2 | Phase 4 | United States |
| 104 | NCT01696708 (ClinicalTrials.gov) | December 6, 2012 | 20/9/2012 | Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease | Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease | Huntington Disease | Other: 31-Phosphorus RMN Spectroscopy | Institut National de la Santé Et de la Recherche Médicale, France | NULL | Completed | 18 Years | N/A | All | 50 | N/A | France |
| 105 | NCT01914965 (ClinicalTrials.gov) | June 2012 | 31/7/2013 | Apathy Cure Through Bupropion in Huntington's Disease | A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease | Apathy;Huntington's Disease | Drug: Bupropion;Drug: Placebo | Charite University, Berlin, Germany | University of Ulm;Ruhr University of Bochum;University Hospital Muenster | Completed | 25 Years | 75 Years | Both | 40 | Phase 2 | Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT01590888 (ClinicalTrials.gov) | April 2012 | 18/4/2012 | Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease | Huntington Disease | Drug: PBT2;Drug: Placebo | Prana Biotechnology Limited | NULL | Completed | 25 Years | N/A | All | 109 | Phase 2 | United States;Australia |
| 107 | NCT01573819 (ClinicalTrials.gov) | November 24, 2011 | 16/2/2012 | A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 | A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 | Huntington Disease | Drug: GSK356278;Drug: Placebo | GlaxoSmithKline | NULL | Completed | 18 Years | 65 Years | All | 36 | Phase 1 | Netherlands |
| 108 | NCT01602900 (ClinicalTrials.gov) | November 22, 2011 | 1/12/2011 | Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease | An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s) | Huntington Disease | Drug: GSK356278;Drug: Rolipram | GlaxoSmithKline | NULL | Completed | 22 Years | 55 Years | Male | 8 | Phase 1 | United Kingdom |
| 109 | NCT01485965 (ClinicalTrials.gov) | November 2011 | 29/11/2011 | A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease | A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196 | Huntington's Disease | Drug: SEN0014196 | Siena Biotech S.p.A. | NULL | Completed | 25 Years | 65 Years | Both | 26 | Phase 1 | United States |
| 110 | NCT01521585 (ClinicalTrials.gov) | November 2011 | 26/1/2012 | A Phase II Safety and Tolerability Study With SEN0014196 | A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196 | Huntington's Disease | Drug: SEN0014196;Drug: Placebo | Siena Biotech S.p.A. | NULL | Completed | 30 Years | 70 Years | Both | 144 | Phase 2 | Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | EUCTR2011-001131-23-GB (EUCTR) | 24/10/2011 | 18/07/2011 | A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease. | A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A | Huntington's disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat | Siena Biotech SpA | NULL | Not Recruiting | Female: yes Male: yes | 144 | Germany;Italy;United Kingdom | |||
| 112 | EUCTR2011-001131-23-IT (EUCTR) | 20/10/2011 | 22/11/2011 | A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease. | A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196 | Huntington's disease MedDRA version: 14.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 14.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat | SIENA BIOTECH SPA | NULL | Not Recruiting | Female: yes Male: yes | 144 | Germany;United Kingdom;Italy | |||
| 113 | EUCTR2011-001131-23-DE (EUCTR) | 21/09/2011 | 27/06/2011 | A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease. | A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A | Huntington's disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat | Siena Biotech SpA | NULL | Not Recruiting | Female: yes Male: yes | 144 | Germany;Italy;United Kingdom | |||
| 114 | NCT01502046 (ClinicalTrials.gov) | September 2011 | 29/12/2011 | Neuroprotection by Cannabinoids in Huntington's Disease | A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease | Huntington's Disease | Drug: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD);Drug: Placebo | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | GW Pharmaceuticals Ltd. | Completed | 18 Years | N/A | Both | 25 | Phase 2 | Spain |
| 115 | NCT01357681 (ClinicalTrials.gov) | September 2011 | 19/5/2011 | Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) | Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial - | Huntington Disease | Drug: (2)-epigallocatechin-3-gallate (EGCG);Drug: Placebo | Charite University, Berlin, Germany | NULL | Completed | 18 Years | N/A | Both | 54 | Phase 2 | Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | NCT01458470 (ClinicalTrials.gov) | September 2011 | 20/10/2011 | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study | Huntington Disease | Drug: Memantine;Other: Placebo | University of British Columbia | Huntington Society of Canada;Huntington Study Group | Completed | 18 Years | 75 Years | All | 19 | Phase 2 | Canada |
| 117 | NCT01306929 (ClinicalTrials.gov) | March 1, 2011 | 28/2/2011 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART). | Huntington Disease | Drug: pridopidine | Prilenia | NULL | Completed | N/A | N/A | All | 235 | Phase 2 | United States;Canada |
| 118 | NCT01485952 (ClinicalTrials.gov) | March 2011 | 29/11/2011 | An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 | An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196. | Huntington Disease | Drug: SEN0014196 (Low Dose);Drug: SEN0014196 (High Dose);Drug: Placebo | Siena Biotech S.p.A. | Seventh Framework Programme;European Huntington's Disease Network | Completed | 18 Years | 70 Years | Both | 55 | Phase 1 | Germany |
| 119 | NCT02101957 (ClinicalTrials.gov) | October 2010 | 25/3/2014 | Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) | Huntington's Disease | Drug: RP103;Drug: Placebo | University Hospital, Angers | NULL | Active, not recruiting | 18 Years | 65 Years | Both | 96 | Phase 2;Phase 3 | France | |
| 120 | EUCTR2009-018123-32-SE (EUCTR) | 30/09/2010 | 10/06/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | EUCTR2009-018123-32-NL (EUCTR) | 23/08/2010 | 14/04/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| 122 | EUCTR2009-018123-32-IT (EUCTR) | 28/07/2010 | 15/07/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-Plus | Huntington`s Corea MedDRA version: 9.1;Level: LLT;Classification code 10020469 | Product Name: Dimebon INN or Proposed INN: Dimebon dihydrochloride Product Name: Dimebon INN or Proposed INN: Dimebon dihydrochloride | MEDIVATION, INC. | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| 123 | EUCTR2009-018119-14-GB (EUCTR) | 23/07/2010 | 18/06/2010 | Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study | Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study | Huntington's Disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | United Kingdom | |||
| 124 | EUCTR2010-019444-39-FR (EUCTR) | 18/06/2010 | 04/05/2010 | Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HD | Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HD | Maladie de Huntington. MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Cysteamine Bitartrate Product Code: RP 103 | Centre Hospitalier Universitaire d'Angers | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 125 | EUCTR2009-018123-32-DE (EUCTR) | 07/06/2010 | 02/03/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 126 | EUCTR2009-018123-32-GB (EUCTR) | 14/05/2010 | 18/03/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | |||
| 127 | EUCTR2009-018123-32-DK (EUCTR) | 23/04/2010 | 16/03/2010 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden | |||
| 128 | NCT01411163 (ClinicalTrials.gov) | April 2010 | 4/8/2011 | Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability | Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability | Huntington's Disease | Drug: Creatine monohydrate | Massachusetts General Hospital | National Institutes of Health (NIH) | Completed | 26 Years | N/A | Both | 24 | Phase 2 | United States |
| 129 | NCT00920699 (ClinicalTrials.gov) | February 2010 | 9/6/2009 | Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) | A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease | Huntington's Disease | Drug: CoQ10 | Johns Hopkins University | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 18 Years | N/A | All | 90 | Phase 2 | United States |
| 130 | NCT01085266 (ClinicalTrials.gov) | February 2010 | 10/3/2010 | An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | Huntington Disease | Drug: Dimebon (latrepirdine) | Medivation, Inc. | Pfizer;Pfizer | Terminated | 30 Years | N/A | Both | 362 | Phase 3 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 131 | EUCTR2009-011800-44-NL (EUCTR) | 20/01/2010 | 28/09/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | Huntington disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Phase 3 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | ||
| 132 | EUCTR2009-011800-44-IT (EUCTR) | 22/12/2009 | 04/11/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease Version 2.0 08 May 2009 - DIM20 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease Version 2.0 08 May 2009 - DIM20 | Patients with Mild-to-Moderate Huntington Disease MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Name: Dimebon INN or Proposed INN: Dimebon dihydrochloride | MEDIVATION, INC. | NULL | Not Recruiting | Female: yes Male: yes | 350 | Phase 3 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | ||
| 133 | EUCTR2009-011743-39-GB (EUCTR) | 15/12/2009 | 21/08/2009 | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea | Huntington's disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 64 | Germany;United Kingdom | |||
| 134 | EUCTR2009-011800-44-SE (EUCTR) | 14/12/2009 | 23/09/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | Huntington disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Phase 3 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | ||
| 135 | NCT01019473 (ClinicalTrials.gov) | November 2009 | 19/11/2009 | Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea | A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea | Huntington's Disease;Chorea | Drug: AFQ056;Drug: Placebo | Novartis Pharmaceuticals | NULL | Terminated | 30 Years | 85 Years | Both | 44 | Phase 2 | Germany;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 136 | EUCTR2009-011800-44-GB (EUCTR) | 07/10/2009 | 05/06/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | Huntington disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Phase 3 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | ||
| 137 | EUCTR2009-011800-44-DE (EUCTR) | 07/10/2009 | 06/07/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | Huntington disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Phase 3 | Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden | ||
| 138 | NCT00988624 (ClinicalTrials.gov) | October 2009 | 1/10/2009 | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | Alzheimer's Disease;Huntington Disease | Drug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4 | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 20 | Phase 1 | United States |
| 139 | NCT00975481 (ClinicalTrials.gov) | October 2009 | 10/9/2009 | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | Alzheimer's Disease;Huntington's Disease | Drug: dimebon;Drug: placebo;Drug: alprazolam | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | All | 36 | Phase 1 | Canada |
| 140 | NCT00990613 (ClinicalTrials.gov) | October 2009 | 6/10/2009 | A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin | A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon IR;Drug: Dimebon Transdermal | Pfizer | Medivation, Inc. | Completed | 50 Years | 85 Years | Both | 19 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 141 | NCT01521832 (ClinicalTrials.gov) | October 2009 | 13/1/2012 | Escalating Dose Study in Healthy Volunteers With SEN0014196 | A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196 | Huntington's Disease | Drug: SEN0014196 | Siena Biotech S.p.A. | NULL | Completed | 18 Years | 65 Years | Both | 88 | Phase 1 | United Kingdom |
| 142 | EUCTR2009-011743-39-DE (EUCTR) | 18/09/2009 | 20/08/2009 | Efficacy, Safety and Tolerability of AFQ056 in Patients with Huntington's Disease in Reducing Chorea | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea | Huntington's disease MedDRA version: 13.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | United States;Germany;United Kingdom | |||
| 143 | EUCTR2009-011800-44-DK (EUCTR) | 11/09/2009 | 04/08/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | Huntington disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride Product Name: Dimebon Product Code: Dimebon INN or Proposed INN: Dimebon dihydrochloride Other descriptive name: Dimebon dihydrochloride | Medivation, Inc | NULL | Not Recruiting | Female: yes Male: yes | 350 | Phase 3 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | ||
| 144 | NCT00980694 (ClinicalTrials.gov) | September 2009 | 17/9/2009 | Bioavailability of Ubiquinol in Huntington Disease | Bioavailability of Ubiquinol in Huntington Disease | Huntington Disease | Dietary Supplement: ubiquinol | University of Rochester | Kaneka Corporation | Completed | 18 Years | N/A | Both | 6 | Phase 1 | United States |
| 145 | NCT00712426 (ClinicalTrials.gov) | September 2009 | 8/7/2008 | Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) | Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) | Huntington's Disease | Drug: Creatine Monohydrate;Drug: Placebo | Massachusetts General Hospital | University of Rochester;National Center for Complementary and Integrative Health (NCCIH) | Terminated | 18 Years | N/A | Both | 553 | Phase 3 | United States;Australia;Canada;New Zealand |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 146 | NCT00970229 (ClinicalTrials.gov) | July 2009 | 31/8/2009 | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls | Parkinson Disease;Huntington Disease | Drug: [123I]MNI-420 | Institute for Neurodegenerative Disorders | NULL | Completed | 18 Years | N/A | All | 19 | Phase 1 | United States |
| 147 | NCT00920946 (ClinicalTrials.gov) | July 2009 | 12/6/2009 | A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington Disease | Huntington Disease | Drug: Dimebon;Other: Placebo | Medivation, Inc. | Pfizer;Pfizer | Completed | 30 Years | N/A | Both | 403 | Phase 3 | United States;Australia;Canada;Denmark;Germany;Sweden;United Kingdom |
| 148 | NCT00931073 (ClinicalTrials.gov) | July 2009 | 1/7/2009 | A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers | A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon alone;Drug: Dimebon + Ketoconazole;Drug: Dimebon + Omeprazole | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 24 | Phase 1 | United States |
| 149 | NCT01411150 (ClinicalTrials.gov) | May 2009 | 4/8/2011 | Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study | Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study | Huntington's Disease | Drug: Creatine Monohydrate | Massachusetts General Hospital | National Institutes of Health (NIH) | Completed | 26 Years | N/A | Both | 38 | Phase 2 | United States |
| 150 | NCT00907595 (ClinicalTrials.gov) | May 2009 | 20/5/2009 | Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon | Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial | Huntington's Disease;Parkinson's Disease;Dementia With Lewy Bodies;Sleep Disorders;Circadian Dysregulation | Drug: Ramelteon;Drug: Placebo | Massachusetts General Hospital | NULL | Withdrawn | 20 Years | 90 Years | Both | 0 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 151 | EUCTR2007-004988-22-AT (EUCTR) | 02/04/2009 | 19/02/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 152 | NCT00632645 (ClinicalTrials.gov) | April 2009 | 29/2/2008 | Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride | Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study. | Huntington Disease | Drug: Olanzapine;Drug: Xenazine;Drug: Tiapridal | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | All | 180 | Phase 3 | France |
| 153 | NCT00870974 (ClinicalTrials.gov) | March 2009 | 26/3/2009 | A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions | Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions | Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment | Drug: [18F]FPEB | Institute for Neurodegenerative Disorders | NULL | Completed | 18 Years | 85 Years | All | 48 | Phase 1 | United States |
| 154 | NCT00831506 (ClinicalTrials.gov) | February 2009 | 27/1/2009 | Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects | Alzheimer Disease;Huntington Disease | Drug: digoxin;Drug: dimebon | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 12 | Phase 1 | United States |
| 155 | NCT00825084 (ClinicalTrials.gov) | February 2009 | 12/1/2009 | A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects | A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 45 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 156 | NCT00824590 (ClinicalTrials.gov) | February 2009 | 12/1/2009 | A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function | A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon | Pfizer | Medivation, Inc. | Completed | 18 Years | 75 Years | Both | 20 | Phase 1 | United States |
| 157 | NCT00827034 (ClinicalTrials.gov) | February 2009 | 20/1/2009 | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Warfarin;Drug: Dimebon | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | All | 14 | Phase 1 | United States |
| 158 | NCT00788047 (ClinicalTrials.gov) | November 2008 | 7/11/2008 | A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects | Huntington Disease;Alzheimer Disease | Drug: Dextromethorphan;Drug: Dimebon + Dextromethorphan | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 14 | Phase 1 | United States |
| 159 | NCT00724048 (ClinicalTrials.gov) | October 2008 | 24/7/2008 | A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease | A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART) | Huntington Disease | Drug: ACR16 10 mg;Drug: ACR16 22.5 mg;Drug: ACR16 45 mg;Other: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 30 Years | N/A | Both | 227 | Phase 2;Phase 3 | United States;Canada |
| 160 | EUCTR2007-002977-30-FR (EUCTR) | 02/09/2008 | 28/08/2008 | Essai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HD | Essai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HD | Maladie de Huntigton (MH): maladie neurodégénérative d’origine génétique. Elle associe des troubles moteurs, psychiatriques et cognitifs (dégénérescence neuronale dans le striatum). Aucun traitement validé n’existe à ce jour. MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Trade Name: CYSTAGON Product Name: CYSTAGON | Centre Hospitalier Universitaire d'Angers | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 161 | EUCTR2007-004988-22-IT (EUCTR) | 26/08/2008 | 29/07/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington?s Disease - ND | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington?s Disease - ND | Huntington's Disease | Product Code: ACR16 | NEUROSEARCH SWEDEN AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 162 | EUCTR2007-004988-22-PT (EUCTR) | 06/06/2008 | 14/02/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 163 | EUCTR2007-004988-22-ES (EUCTR) | 03/06/2008 | 11/02/2008 | Un estudio multicentro, internacional, aleatorizado, doble ciego y de grupos paralelos que compara la administración de ACR16 45 mg una o dos veces al día frente al placebo, para el tratamiento sintomático de la Enfermedad de Huntington.(A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease) - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Un estudio multicentro, internacional, aleatorizado, doble ciego y de grupos paralelos que compara la administración de ACR16 45 mg una o dos veces al día frente al placebo, para el tratamiento sintomático de la Enfermedad de Huntington.(A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease) - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Enfermedad de Huntington (Huntington's Disease) MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 164 | EUCTR2007-004988-22-FR (EUCTR) | 23/05/2008 | 08/01/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 165 | NCT00665223 (ClinicalTrials.gov) | April 2008 | 22/4/2008 | A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease | A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease | Huntington's Disease | Drug: ACR16;Drug: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 30 Years | N/A | Both | 437 | Phase 3 | Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 166 | NCT00608881 (ClinicalTrials.gov) | March 2008 | 4/2/2008 | Coenzyme Q10 in Huntington's Disease (HD) | Coenzyme Q10 in Huntington's Disease (HD) | Huntington's Disease | Drug: coenzyme Q10;Other: placebo | Massachusetts General Hospital | National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester | Terminated | 16 Years | N/A | All | 609 | Phase 3 | United States;Australia;Canada |
| 167 | EUCTR2007-004988-22-DE (EUCTR) | 22/02/2008 | 26/10/2007 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;France;Spain;Belgium;Austria;Germany;Italy;United Kingdom | |||
| 168 | EUCTR2007-004988-22-GB (EUCTR) | 11/01/2008 | 16/10/2007 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 169 | EUCTR2007-004988-22-BE (EUCTR) | 04/01/2008 | 30/10/2007 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 170 | NCT00592995 (ClinicalTrials.gov) | December 2007 | 28/12/2007 | Creatine Safety and Tolerability in Premanifest HD: PRECREST | Creatine Safety and Tolerability in Premanifest HD: PRECREST | Huntington Disease | Drug: Creatine monohydrate;Drug: Placebo | Massachusetts General Hospital | NULL | Completed | 26 Years | N/A | Both | 64 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 171 | EUCTR2007-003293-25-GB (EUCTR) | 20/11/2007 | 26/07/2007 | A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMOND | A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMOND | Huntington's disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Medivation, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 2 | United Kingdom | |||
| 172 | NCT00514774 (ClinicalTrials.gov) | August 2007 | 8/8/2007 | Ursodiol in Huntington's Disease | Ursodiol in Huntington's Disease | Huntington Disease | Drug: ursodiol;Drug: placebo | Oregon Health and Science University | Huntington Study Group;Huntington Society of Canada | Active, not recruiting | 18 Years | N/A | Both | 21 | Phase 1 | United States |
| 173 | NCT00497159 (ClinicalTrials.gov) | July 2007 | 3/7/2007 | A Study of the Novel Drug Dimebon in Patients With Huntington's Disease | A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease | Huntington's Disease | Other: Placebo;Drug: Dimebon | Medivation, Inc. | Huntington Study Group | Completed | 29 Years | N/A | Both | 90 | Phase 2 | United States |
| 174 | NCT00387270 (ClinicalTrials.gov) | October 2006 | 10/10/2006 | Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease | A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease | Huntington's Disease | Drug: Dimebon | Medivation, Inc. | Huntington Study Group | Completed | 18 Years | N/A | Both | 9 | Phase 1;Phase 2 | United States |
| 175 | EUCTR2005-002088-98-PT (EUCTR) | 07/06/2006 | 16/03/2006 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl Icosapent Other descriptive name: Ethyl-EPA | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | Portugal;Germany;United Kingdom;Spain;Italy | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 176 | NCT00277355 (ClinicalTrials.gov) | April 2006 | 12/1/2006 | Pilot Study of Minocycline in Huntington's Disease | A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease | Huntington Disease | Drug: minocycline;Drug: Matching placebo | Merit Cudkowicz | FDA Office of Orphan Products Development | Completed | 18 Years | N/A | All | 114 | Phase 2;Phase 3 | United States;Canada |
| 177 | EUCTR2005-002088-98-ES (EUCTR) | 29/12/2005 | 04/10/2005 | Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington. | Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington. | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: llt;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 | Amarin Neuroscience Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Portugal;Germany;United Kingdom;Spain;Italy | ||||
| 178 | EUCTR2005-002088-98-AT (EUCTR) | 01/12/2005 | 27/10/2005 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl-Icosapent | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | 240 | Portugal;Spain;Austria;Germany;Italy;United Kingdom | |||
| 179 | EUCTR2005-002088-98-GB (EUCTR) | 07/11/2005 | 18/08/2005 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | Portugal;Germany;United Kingdom;Spain;Italy | ||||
| 180 | NCT00368849 (ClinicalTrials.gov) | November 2005 | 24/8/2006 | Atomoxetine and Huntington's Disease | Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study | Huntington Disease;Chorea | Drug: atomoxetine;Drug: Matching Placebo | University of Iowa | Eli Lilly and Company | Completed | 18 Years | 65 Years | All | 20 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 181 | NCT00271596 (ClinicalTrials.gov) | November 2005 | 30/12/2005 | Citalopram to Enhance Cognition in HD | A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) | Huntington Disease;Chorea;Executive Dysfunction | Drug: 20mg daily citalopram;Drug: Placebo | University of Iowa | National Institute of Neurological Disorders and Stroke (NINDS);Cure Huntington's Disease Initiative (CHDI);University of Rochester;Mayo Clinic | Completed | 18 Years | 75 Years | All | 33 | Phase 2 | United States |
| 182 | NCT00146211 (ClinicalTrials.gov) | September 2005 | 2/9/2005 | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease | A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease | Huntington Disease | Drug: Ethyl-EPA (Miraxion™) | Amarin Neuroscience Ltd | Huntington Study Group | Completed | 35 Years | N/A | Both | 300 | Phase 3 | United States;Canada |
| 183 | NCT00212316 (ClinicalTrials.gov) | August 2005 | 19/9/2005 | Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) | Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's Disease | Huntington's Disease | Drug: sodium phenylbutyrate | University of Rochester | HP Therapeutics Foundation;Massachusetts General Hospital;Columbia University;University of Iowa;University of California, San Diego;University of Kansas;University of Alabama at Birmingham;Johns Hopkins University | Completed | 18 Years | N/A | Both | 60 | Phase 2 | United States |
| 184 | NCT01412151 (ClinicalTrials.gov) | April 2005 | 5/8/2011 | Creatine Safety & Tolerability in Huntington's Disease | Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD | Huntington's Disease (HD) | Drug: Creatine monohydrate | Massachusetts General Hospital | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 185 | NCT00652457 (ClinicalTrials.gov) | November 23, 2004 | 31/3/2008 | Study of Memantine to Treat Huntington's Disease | A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease | Huntington's Disease | Drug: Memantine | Jody Corey-Bloom, MD, PhD | Forest Laboratories | Completed | 18 Years | N/A | All | 60 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 186 | EUCTR2004-000394-60-DK (EUCTR) | 05/10/2004 | 17/08/2004 | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists. | Product Name: ACR16 Product Code: ACR16 | A. Carlsson Research AB | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Denmark;Sweden | ||
| 187 | NCT00095355 (ClinicalTrials.gov) | October 2004 | 2/11/2004 | Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease | Stimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's Disease | Huntington's Disease | Drug: Lithium;Drug: Divalproex | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 35 | Phase 2 | United States |
| 188 | EUCTR2004-000394-60-SE (EUCTR) | 30/06/2004 | 13/05/2004 | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists. | Product Name: ACR16 Product Code: ACR16 | A. Carlsson Research AB | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Denmark;Sweden | ||
| 189 | NCT00190450 (ClinicalTrials.gov) | January 2002 | 15/9/2005 | MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease | Multicentric Intracerebral Grafting in Huntington's Disease | Huntington Disease | Biological: graft intracerebral of foetal neurons | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | 65 Years | All | 54 | Phase 2 | France |
| 190 | NCT00026988 (ClinicalTrials.gov) | October 2001 | 15/11/2001 | Creatine Therapy for Huntington's Disease | Creatine Therapy for Huntington's Disease | Huntington's Disease | Drug: Creatine | National Center for Complementary and Integrative Health (NCCIH) | NULL | Completed | 18 Years | N/A | Both | 64 | Phase 1;Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 191 | NCT00029874 (ClinicalTrials.gov) | September 2001 | 24/1/2002 | Minocycline in Patients With Huntington's Disease | Minocycline Dosing and Safety in Huntington's Disease | Huntington's Disease | Drug: Minocycline | FDA Office of Orphan Products Development | NULL | Completed | 18 Years | N/A | Both | 63 | Phase 1;Phase 2 | United States |
| 192 | NCT00219804 (ClinicalTrials.gov) | January 2000 | 14/9/2005 | Efficacy and Safety of Tetrabenazine in Chorea | A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea | Huntington's Disease | Drug: tetrabenazine or placebo | Prestwick Pharmaceuticals | NULL | Completed | 18 Years | N/A | Both | Phase 3 | NULL | |
| 193 | NCT00277602 (ClinicalTrials.gov) | November 1999 | 13/1/2006 | Riluzole in Huntington's Disease | A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease | Huntington Disease | Drug: Riluzole | Sanofi | NULL | Completed | 25 Years | 65 Years | Both | 537 | Phase 3 | NULL |
| 194 | NCT00001930 (ClinicalTrials.gov) | April 1999 | 3/11/1999 | Treatment of Huntington's Chorea With Amantadine | NMDA-Receptor Blockade in Huntington's Chorea | Chorea;Huntington's Disease | Drug: Amantadine | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 25 | Phase 2 | United States |
| 195 | EUCTR2005-002088-98-DE (EUCTR) | 28/11/2006 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl-Icosapent | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | 240 | Portugal;United Kingdom;Germany;Spain;Italy | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 196 | EUCTR2016-005095-10-DE (EUCTR) | 04/06/2019 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 1;Phase 2 | France;Canada;Poland;Denmark;Australia;Germany;United Kingdom | |||
| 197 | EUCTR2016-005142-39-DE (EUCTR) | 04/06/2019 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease | Huntington’s Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120102 Product Code: WVE-120102 INN or Proposed INN: WVE-120102 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 1;Phase 2 | France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom |